Alzheimer's disease & dementia

The two obstacles that are holding back Alzheimer's research

Thirty years ago, scientists began to unlock the mysteries regarding the cause of Alzheimer's disease. This knowledge ushered in an era of great enthusiasm that scientists could develop new therapies to either prevent Alzheimer's ...

Medications

Extending Rx exclusivity could boost study for rare diseases

(HealthDay)—Extending the market exclusivity for existing drugs that are granted subsequent U.S. Food and Drug Administration (FDA) approval for a new rare disease indication would provide manufacturers with substantial ...

Medications

Can the high cost of prescription drugs in the US be contained?

In a Special Communication in JAMA, "The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform," Kesselheim and colleagues reviewed the peer reviewed medical and health policy literature from ...

Medications

Fast-tracking rare disease drug candidates' approval

Aspiring new drugs face long and stringent tests on safety and effectiveness before making it to market. And rightly so. But giving drugs special designations that bring with them the right incentives can help bring them ...

Medications

Pharmaceutical intellectual property laws need reform

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Medications

Drug prices to plummet in wave of expiring patents

The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol ...